GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer

Table 2 The association of clinical character with preoperative serum levels of CA125 and GDF15 levels in 122 EOC patients

Patient number	Total population (n = 122)	Debulking surgery		P-value	Chemotherapeutic response		P-value
Patient number	Total population (n = 122)	optimal(n = 84)	Suboptimal (n = 38)	P-value	Chemosensitive(n = 91)	Chemoresistant(n = 31)	P-value
Age (mean ± s.d.)	53.4 ± 11.1	52.6 ± 11.6	55.1 ± 9.7	0.251^a	52.4 ± 11.2	54.8 ± 10.9	0.302^a
Histology
Serous	90 (73.8%)	61	29	0.836^b	66	24	0.765^b
Non-serous	32 (26.2%)	23	9		25	7
FIGO
Stage I/ II	13 (10.7%)	11	2	0.341^b	13	0	0.037^b
Stage III/IV	109 (89.3%)	73	36		78	31
Grading
Low/Medium	41 (58.2%)	29	12	0.911^b	32	9	0.686^b
High	81 (41.8%)	55	26		59	22
Debulking surgery
Optimal	84 (68.9%)				62	22	0.944^b
Suboptimal	38 (31.1%)				29	9
LN metastasis
Yes	69 (56.6%)	43	26	0.114^b	48	21	0.213^b
No	53 (43.4%)	41	12		43	10
CA125 (median,U/L)	54.7	34.4	106.8	0.043^c	33.1	74.6	0.108 ^c
GDF15 (median,pg/mL)	920.9	933.3	915.4	0.596^c	824.2	1225.0	0.013 ^c

a. The p value was calculated using t-test; b. The p value was calculated using Chi-squared test; c. The p value was calculated using Mann-Whitney test

ISSN: 1471-2407